2-AMINO- 1,3,4-THIADIAZOLE AS AN ANTIMICROBIAL

SCAFFOLD

More A. L^* ¹

¹Department of Chemistry, BV'S Matoshri Bayabai Shripatrao Kadam Kanya Mahavidyalaya, Kadegaon, Dist- Sangli. (MS) -415304, India. e-mail-

Dr. A. M. Chougule ²

²Department of Industrial Chemistry, Dayanand Science College, Latur. (MS) -413512,

India

J. V. Kuwar³

³Department of Microbiology, BV'S Matoshri Bayabai Shripatrao Kadam Kanya Mahavidyalaya, Kadegaon, Dist- Sangli. (MS) -415304, India. e-mail-

Abstract

Infections caused by bacteria and fungi continue to be a problem in healthcare despite advances in medicine. There is a lot of interest in the development of new antimicrobial compounds as more bacteria become resistant to antibiotics used in therapy and more invasive fungal species become resistant to existing antifungal medications. Among the organic chemicals with biological activity used as medications in human and veterinary medicine or as insecticides and pesticides in agriculture, heterocyclic compounds are crucial. Thiadiazoles are nitrogen-sulfur heterocycles with a variety of uses in both medicinal chemistry and as the structural building blocks of biologically active molecules. The effectiveness of the thiadiazole nucleus is shown by the drugs that are currently being used. 1,3,4-thiadiazoles and some of their derivatives have been the subject of in-depth research because of their wide range of pharmacological activities. The main goal of this research was to highlight the 2-amino-1,3,4-thiadiazole moiety-containing derivatives' primary antimicrobial properties. The versatile moiety thiadiazole has a wide range of biological functions. A "hydrogen binding domain" and a "two-electron donor system" are the roles played by the thiadiazole moiety. Also covered are substituted 2-amino-1,3,4-thiadiazole and its derivatives that exhibit antimicrobial activity. **Keywords:** Antimicrobial, Anti-fungal, Thiadiazole, pharmacological.

Introduction:

Heterocyclic compounds are well known for their pharmacological potential which is exploitable in the synthesis of new bioactive molecules. Moreover, nowadays heterocyclic chemistry has become more and more advanced in the development of new polyheterocyclic compounds [1].

1,3,4-thiadiazole moiety is a five-membered heterocyclic nucleus bearing nitrogen and sulfur. There are several isomers of thiadiazole, including 1,2,3 Thiadiazole, 1,2,5 Thiadiazole, 1,2,4 Thiadiazole, and 1,3,4 Thiadiazole.

Thiadiazole is the isomer of the thiadiazole series. The literature check revealed that further studies

have been carried out on the thiadiazole half compared to its other isomers combined [2]. Considering that thiadiazole is the bioisostere of pyrimidine and oxadiazole, it isn't surprising that composites bearing this half present a broad diapason of pharmacological parcels, including antiviral, antibacterial, antifungal, antiparasitic, anti-inflammatory and anticancer conditioning [3].

Among the different azole heterocycles, - thiadiazoles have aroused important interest as can be seen from the large number of different synthetic methodologies reported in the literature. likewise, these

composites have veritably diversified natural parcels, $[4-11]$ including antifungal, $[12]$ anti-inflammatory, $[13]$ antibacterial, ^[14] antiparasitic, ^[15] antioxidant, ^[16] antidepressant, anticonvulsant, ^[17] diuretic, ^[18] and antitumoral agents $[19]$ (Figure 1).

Figure 1. Examples of bioactive compounds containing 1,3,4-thiadiazole

This report reviews the evolution of the main syntheses of 1,3,4-thiadiazole derivatives and examples of thiadiazole structure with antimicrobial activity reported over the years.

Material and Methods:

Experimental General:

Substituted benzoic acid (50 mmol) and thiosemicarbazide (50 mmol) were stirred in 25ml of phosphorous Oxychloride in a round-bottomed flask and refluxed under 75-800C for 3 hours. The reaction mixture becomes liquid and fumes of HCl are formed. Cool the reaction mixture and then add 125 ml of ice-cold water drop by drop till the fumes stop. Then reflux direct heating for up to 3-4 hours. After the reaction, the mixture was allowed to cool and neutralize using a 40% potassium hydroxide solution. In addition to the base, the thiadiazole product precipitated and recrystallized from aqueous ethanol. By this method different types of thiadiazole products are formed that are 2-amino-5-(4-bromophenyl)-1,3,4 thiadiazole (Th-1), 2-amino-5-(4-nitrophenyl)-1,3,4-thiadiazole (Th-2), 2-amino-5-(2-chlorophenyl)-1,3,4 thiadiazole (Th-3),2-amino-5-(4-chlorophenyl)-1,3,4-thiadiazole (Th-4),2-amino-5-(2-methyl phenyl)- 1,3,4-thiadiazole (Th-5),2-amino-5-(4-methyl phenyl)-1,3,4-thiadiazole (Th-),2-amino-5-(4 methoxyphenyl)-1,3,4-thiadiazole (Th-7).

Biological Screening:

Antimicrobial Activity:

Agar fragment-prolixity testing developed in $1940^{[20]}$, is the sanctioned system used in numerous clinical microbiology laboratories for routine antimicrobial vulnerability testing. currently, numerous accepted and approved norms are published by the Clinical and Laboratory Norms Institute (CLSI) for bacteria and incentive testing $[21]$, $[22]$. In this well-known procedure, agar plates are invested with a standardized inoculum of the test microorganism. also, sludge paper discs (about 6 mm in the periphery), containing the test emulsion at the asked attention, are placed on the agar face. The Petri dishes are incubated under optimal conditions. Generally, an antimicrobial agent diffuses into the agar and inhibits germination and growth of the test microorganism, and the compasses of inhibition growth zones are measured.

Antibiogram provides qualitative results by grading bacteria as susceptible, intermediate, or resistant [23]. still, since bacterial growth inhibition doesn't mean bacterial death, this system cannot distinguish between bactericidal and bacteriostatic goods.

Also, the agar fragment-prolixity system isn't applicable to determine the minimal inhibitory attention (MIC), as it's insoluble to quantify the quantum of the antimicrobial agent diffused into the agar medium. nonetheless, an approximate MIC can be calculated for some microorganisms and antibiotics by comparing the inhibition zones $[24]$.

Nonetheless, fragment-prolixity assay offers numerous advantages over other styles simplicity, low cost, the capability to test enormous figures of microorganisms and antimicrobial agents, and the ease of interpreting results. This fact is due to the good correlation between the in vitro data and the in vivo elaboration^[25].

Presently, a standardized antifungal fragment-prolixity approach is used to test dermatophyte filamentous fungi [26].

The below-mentioned advantages of this system, substantial simplicity, and low cost, have

contributed to its common use for the antimicrobial webbing of factory excerpts, essential canvases, and

other medicines [27,28,29,30] .

Table 1.

Results: Antimicrobial activity of synthesized compound:

Table 1. Antimicrobial activity is expressed as inhibition diameter zones in millimeters (mm) of compounds Th-1 to Th-7 against the microbial and fungal strains based on Disk diffusion assay.

The experiment was carried out in triplicate and the average zone of inhibition was calculated (100 µL was tested) (N.A. = no activity), data is expressed in the form of mean \pm SD.

Discussion:

Emulsions Th- 1 to Th- 7 all show high energy against E. coli gram-negative bacteria. Th- 1, Th-3, Th- 5, and Th- 6 show good antifungal exertion against Aspergillus. Among these composites, Th- 1 and Th- 3 show high energy compared to others. For the fungus candida Albicans, emulsion Th- 1 shows good exertion and Th- 5 shows moderate exertion. For Bacillus Th- 2 to Th- 7 showed moderate antimicrobial exertion and for Pseudomonas Th- 1, Th- 2, Th- 3, Th- 6, and Th- 7 showed moderate antimicrobial exertion. Th- 4 and Th- 7 show no antifungal exertion against Aspergillus also Th- 2 and Th- 6 show no antifungal exertion against candida Albicans. Th- 4 and Th- 5 have no exertion against gram-negative bacteria i.e. Pseudomonas.

The results of antimicrobial conditioning for some of the recently synthesized composites showed promising goods. In the present exploration work, the antibacterial exertion of synthesized Thiadiazol was performed by the Agar Disk prolixity system, it was observed that composites have some significant exertion against Gram-positive, Fungi, and Gram-negative bacteria. It could therefore be assessed that the antimicrobial exertion of substituted- thiadiazole is a unique template with significant mileage in medicinal chemistry. The studies revealed that antimicrobial exertion is dependent on the nature of the substituent at the thiadiazole nucleus.

Conclusion:

Thiadiazole ring has colorful natural conditioning. Amongst the isomers of thiadiazole, thiadiazole is extensively studied due to its broad scale of pharmacological conditioning. Though many pharmacological goods are displayed by thiadiazole which is presently used clinically (e.g., antibacterial exertion and carbonic anhydrase inhibiting exertion), the negotiation at the Thiadiazole ring is a clamant approach to carrying agents with bettered energy and lower toxin. Although antibacterial exertion, has been studied, other antimicrobial conditioning displayed similarly as antifungal and antitubercular parcels can also be explored. The antimicrobial exertion results of the products indicated that some of the recently synthesized- thiadiazole composites showed promising exertion. Literature checks report the antimicrobial exertion of substituted 2-amino, making 2-amino a unique template with significant mileage in medicinal chemistry. numerous 2-amino derivations can be considered supereminent composites for medicine development. The SAR studies revealed that antimicrobial exertion is dependent on the nature of the substituents at the thiadiazole nucleus.

Reference:

[1]. Sreenivasa GM, Jayachandran E, Jayaraj Kumar K, Srinivas Rao D. Synthesis of Bioactive molecules Fluoro Substituted Benzothiazole comprising potent heterocyclic moieties for biological and pharmacological screening. J Res Rev Biomed Biotech 2010;1(1):24-30.

[2]. Mathew V, Keshavayya J, Vaidya VP, Giles D. Studies on the synthesis and pharmacological activities of 3,6-disubstituted1,2,4-triazolo[3,4-b]-1,3,4-thiadiazoles and their dihydro. Eur J Med Chem 2007; 42:823-40.

[3]. Li Y, Geng J, Liu Y, Yu S, Zhao G. Thiadiazole-a promising structure in medicinal chemistry. ChemMedChem. 2013; 8:27–41. https://doi.org/10.1002/cmdc.201200355.

[4]. Zou, X.; Lai, L.; Jin, G.; Zhang, Z. Synthesis, fungicidal activity, and 3D-QSAR of pyridazinesubstituted 1,3,4-oxadiazoles and 1,3,4-thiadiazoles. Journal of Agricultural and Food Chemistry 2002, 50, 3757.

[5]. Altintop, M. D.; Ciftci, H. I.; Radwan, M. O.; Sever, B.; Kaplancikli, Z. A.; Ali, T. F. S.; Koga, R.; Fujita, M.; Otsuka, M.; Özdemir, A. Design, synthesis, and biological evaluation of novel 1,3,4-thiadiazole derivatives as potential antitumor agents against chronic myelogenous leukemia: Striking effect of nitro thiazole moiety. Molecules 2018, 23, 59.

[6]. Srivastava, S.; Prasad, R. K.; Saini, R. Thiadiazole: A brief review. World Journal of Pharmacy and Pharmaceutical Sciences 2014, 3, 1198.

[7]. Pandit, N.; Shah, K.; Agrawal, N.; Upmanyu, N.; Shrivastava, S. K.; Mishra, P.Synthesis, characterization and biological evaluation of some novel fluoroquinolones. Medicinal Chemistry Research 2016, 25, 843.

[8]. Kumar, K. R.; Rani, B. L. Synthesis, characterization and biological evaluation of [2-(substituted aryl)- 3-[5-(substituted phenyl)-1,3,4-thiadiazole]-4-oxothiazolidines. European Journal Biomedical and Pharmaceutical Sciences 2016, 3, 288.

[9]. Manimaran, T.; Anand, R. M.; Jishala, M.; Gopalasatheeskumar, K.; Parthiban, S.; Boopathi, T. Synthesis, and characterization of substituted 1,3,4 thiadiazole as potential antimicrobial agents. International Journal of Pharmaceutical, Chemical and Biological Sciences 2017, 7, 142.

[10]. Zender, M.; Klein, T.; Henn, C.; Kirsch, B.; Maurer, C. K.; Kail, D.; Ritter, C.; Dolezal, O.; Steinbach, A.; Hartmann, R. W. Discovery and biophysical characterization of 2-aminooxadiazoles as novel antagonists of PqsR, an important regulator of Pseudomonas aeruginosa virulence. Journal Medicinal Chemistry 2013, 56, 6761.

[11]. Padmavathi, V.; Swapna, M.; Premakumari, C.; Reddy, S. N.; Padmaja, A. Synthesis and

antioxidant activity of a variety of sulfonamidomethane linked 1,3,4-oxadiazoles and thiadiazoles. Chemical and Pharmaceutical Bulletin 2013, 61, 611.

[12]. Mullick, P.; Khan, S. A; Verma, S.; Alam, O. Synthesis, characterization and antimicrobial activity of new thiadiazole derivatives. Bulletin of the Korean Chemical Society 2010, 31, 2345.

[13]. Zhu, H.; Hu, Y.; Li, C.; Wang, X. W.; Yang, Y. 1,3,4-Thiadiazole: Synthesis, reactions, and applications in medicinal, agricultural, and materials chemistry. Chemical Reviews 2014, 114, 5572.

[14]. Hamama, W. S.; Raoof, H. A.; Zoorob, H. H.; Ibrahim, M. E. Synthesis of some new binary and spiro heterocyclic thiazolo[4,3-b][1,3,4]thiadiazole ring systems and their antimicrobial evaluation. Der Pharma Chemica 2017, 9, 28.

[15]. Chauviere, G.; Bouteille, B.; Enanga, B.; Albuquerque, C.; Croft, S. L.; Dumas, M.; Périé, J. Synthesis and biological activity of nitro heterocycles analogous to megazol, a Trypanocidal lead. Journal of Medicinal Chemistry 2003, 46, 427.

[16]. Alam, F.; Dey, B. K.Synthesis, characterization and in the vitroanti-oxidant activity of some novel 1,3,4-thiadiazole derivatives. Der Pharma Chemica 2015, 7, 230.

[17]. Pandey, A.; Dewangan, D.; Verma, S.; Mishra, A.; Dubey, R. D. Synthesis of Schiff bases of 2-amino-5-aryl-1,3,4-thiadiazole and its analgesic, anti-inflammatory, anti-bacterial and anti-tubercular activity.International Journal of ChemTech Research 2011, 3, 178.

[18]. Mishra, P.; Upadhyay, P.K. Synthesis, antimicrobial and anticancer activities of 5-(4-substitutedphenyl)-1,3,4-thiadiazole-2-amines. Rasayan Journal of Chemistry 2017, 10, 254. [CrossRef] [19]. Jatav, V.; Mishra, P.; Kashaw, S.; Stables, J. P. Synthesis, and CNS depressant activity of some novel 3- [5 substituted 1,3,4-thiadiazole2-yl]-2-styryl quinazoline-4(3H)-ones European Journal of Medicinal Chemistry 2008, 43, 135.

[20]. N.G. Heatley, A method for the assay of penicillin, Biochem. J., 38 (1944), pp. 61-65

[21]. CLSI, Performance Standards for Antimicrobial Disk Susceptibility Tests, Approved Standard, 7th ed., CLSI document M02-A11. Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087, USA, 2012.

[22]. CLSI, Method for Antifungal Disk Diffusion Susceptibility Testing of Yeasts, Approved Guideline. CLSI document M44-A. CLSI, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898, USA, 2004.

[23]. J.H. Jorgensen, M.J. Ferraro, Antimicrobial susceptibility testing: a review of general principles and contemporary practices, Clin. Infect. Dis., 49 (2009), pp. 1749-1755

[24]. A. Nijs, R. Cartuyvels, A. Mewis, et al., Comparison and evaluation of Osiris and Sirscan 2000 antimicrobial susceptibility systems in the clinical microbiology laboratory, J. Clin. Microbiol., 41 (2003), pp. 3627-3630

[25]. F. Caron, Antimicrobial susceptibility testing: a four facets tool for the clinician, J. Des. Anti-Infect. 14 (2012)

[26]. CLSI, Method for Antifungal Disk Diffusion Susceptibility Testing of Nondermatophyte Filamentous Fungi, Approved guideline, CLSI document M51-A. Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087, USA, 2010.

[27]. L. Fourati-Ben Fguira, S. Fotso, R. Ben Ameur-Mehdi, et al., Purification and structure elucidation of antifungal and antibacterial activities of newly isolated Streptomyces sp. strain US80, Res. Microbiol., 156 (2005), pp. 341-347

[28]. K. Konaté, J.F. Mavoungou, A.N. Lepengué, et al., Antibacterial activity against β-lactamase producing Methicillin and Ampicillin-resistants Staphylococcus aureus: Fractional Inhibitory Concentration Index (FICI) determination, Ann. Clin. Microbiol. Antimicrob., 11 (2012), p. 18

[29]. V.G. De Billerbeck, Huiles Essentielles et Bactéries Résistantes aux Antibiotiques Phytotherapie, 5 (2007), pp. 249-253

[30]. K. Das, R.K.S. Tiwari, D.K. Shrivastava, Techniques for evaluation of medicinal plant products as antimicrobial agents: current methods and future trends J. Med. Plants Res., 4 (2010), pp. 104-1